Here is a synthetic discharge summary for the patient:

**Patient Information:**

* Name: John Doe
* Age: 35 years
* Admission Date: March 10, 2023
* Discharge Date: March 15, 2023

**Chief Complaint:**

John Doe was admitted to the Infectious Diseases Unit on March 10, 2023, with a chief complaint of fever, cough, and fatigue that started on March 5, 2023. He reported a gradual worsening of symptoms over the next few days, with difficulty breathing and chest tightness.

**Medical History:**

John Doe has no significant medical history, except for a history of mild asthma, which was well-controlled with inhalers. He is not immunosuppressed and does not have any chronic medical conditions.

**Physical Examination:**

On admission, John Doe was afebrile, with a temperature of 37.2°C (99°F). His blood pressure was 120/80 mmHg, heart rate was 100 beats per minute, and respiratory rate was 20 breaths per minute. He had diffuse rhonchi and wheezing on auscultation of the lungs. His oxygen saturation was 98% on room air.

**Diagnostic Evaluation:**

A rapid influenza diagnostic test (RIDT) was performed on March 10, 2023, and was negative. However, a real-time reverse transcription polymerase chain reaction (RT-PCR) test was performed on a nasopharyngeal swab and was positive for influenza A (H3N2). The RT-PCR test was repeated on March 12, 2023, and confirmed the diagnosis of influenza A (H3N2).

**Treatment:**

John Doe was started on oseltamivir 75 mg orally twice a day on March 10, 2023, and continued for 5 days. He was also prescribed acetaminophen 325 mg every 4 hours as needed for fever and pain relief. He was advised to rest, stay hydrated, and use a humidifier to relieve congestion.

**Hospital Course:**

John Doe's hospital course was uneventful, except for a brief episode of hypoxemia on March 12, 2023, which was treated with oxygen therapy. He was monitored closely for signs of pneumonia, but none developed.

**Discharge Instructions:**

John Doe was discharged from the hospital on March 15, 2023, with instructions to complete the remaining 2 days of oseltamivir therapy. He was advised to continue using acetaminophen as needed for fever and pain relief, and to follow up with his primary care physician in 1 week. He was also advised to avoid close contact with others for the next 7 days to prevent transmission of the virus.

**Medications:**

* Oseltamivir 75 mg orally twice a day for 5 days
* Acetaminophen 325 mg every 4 hours as needed for fever and pain relief

**Follow-up:**

John Doe is scheduled to follow up with his primary care physician in 1 week to assess his recovery and to evaluate for any potential complications of influenza.

**Conclusion:**

John Doe was admitted to the Infectious Diseases Unit with a diagnosis of influenza A (H3N2) and was treated with oseltamivir and supportive care. He responded well to treatment and was discharged from the hospital on March 15, 2023. He is expected to make a full recovery with continued follow-up care.